UB Paderborn / Katalog / Suche / in CDI

Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis

Journal of clinical gastroenterology, 2020-11, Vol.54 (10), p.911

Modesto, Irene

2020

Link zum Volltext

Verfügbarkeit prüfen

Mesalazine for the treatment of inflammatory bowel disease

Expert opinion on pharmacotherapy, 2013-08, Vol.14 (12), p.1669-1678

2013

Link zum Volltext

Verfügbarkeit prüfen

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

Therapeutic advances in gastroenterology, 2021, Vol.14, p.17562848211005708-17562848211005708

2021

Link zum Volltext

Verfügbarkeit prüfen

Is 5-ASA still the treatment of choice for ulcerative colitis?

Current drug targets, 2011-09, Vol.12 (10), p.1396

2011

Link zum Volltext

Verfügbarkeit prüfen

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Therapeutic advances in gastroenterology, 2021-11, Vol.14, p.17562848211054710-17562848211054710

2021

Link zum Volltext

Verfügbarkeit prüfen

Methodology for high-quality studies on course and prognosis of inflammatory bowel disease

World journal of gastroenterology : WJG, 2012-08, Vol.18 (29), p.3800-3805

2012

Link zum Volltext

Verfügbarkeit prüfen

Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use

Inflammatory intestinal diseases, 2021-12, Vol.6 (4), p.186-198

2021

Link zum Volltext

Verfügbarkeit prüfen

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis

BMJ open gastroenterology, 2020-09, Vol.7 (1), p.e000456

2020

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy

Microorganisms (Basel), 2020-11, Vol.8 (11), p.1792

2020

Link zum Volltext

Verfügbarkeit prüfen

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Annals of the rheumatic diseases, 2023-07, Vol.82 (7), p.901

2023

Link zum Volltext

Verfügbarkeit prüfen

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

Alimentary pharmacology & therapeutics, 2019-11, Vol.50 (10), p.1068-1076

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

Alimentary pharmacology & therapeutics, 2022-02, Vol.55 (4), p.464-478

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

Clinical gastroenterology and hepatology, 2022-03, Vol.20 (3), p.591-601.e8

2022

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

Inflammatory bowel diseases, 2021-04, Vol.27 (4), p.585-589

2021

Link zum Volltext

Verfügbarkeit prüfen

The Role of Portal Vein Thrombosis in the Clinical Course of Inflammatory Bowel Diseases: Report on Three Cases and Review of the Literature

Gastroenterology research and practice, 2012-01, Vol.2012, p.916428-7

2012

Link zum Volltext

Verfügbarkeit prüfen

Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments

Gut, 2021-02, Vol.70 (2), p.418

2021

Link zum Volltext

Verfügbarkeit prüfen

Tu1719 ACHIEVEMENT OF STRINGENT HISTOLOGIC AND COMPOSITE ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1092-S-1093

2023

Link zum Volltext

Verfügbarkeit prüfen

Tu1735 TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG TWICE DAILY (BID) VS REMAINING ON 10 MG BID IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION ON 10 MG BID: UPDATED 30 MONTH DATA FROM THE DOUBLE-BLIND, RANDOMIZED RIVETING STUDY

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1101-S-1102

2023

Link zum Volltext

Verfügbarkeit prüfen

Tu1869 TIME TO LOSS OF EFFICACY AMONG PATIENTS IN REMISSION FOLLOWING INDUCTION TREATMENT WITH TOFACITINIB 10 MG BID WHO REDUCED TOFACITINIB DOSE OR DISCONTINUED TOFACITINIB IN OCTAVE SUSTAIN

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1196-S-1196

2020

Link zum Volltext

Verfügbarkeit prüfen

Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review

Expert review of gastroenterology & hepatology, 2021-09, Vol.15 (9), p.985-997

2021

Link zum Volltext

Verfügbarkeit prüfen

130 WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-36-S-36

2021

Link zum Volltext

Verfügbarkeit prüfen

S924 Cardiovascular Outcome and Cancer Risk in Adult Patients With Ulcerative Colitis in Routine Clinical Care: The Effect of Cardiovascular Risk-Enrichment Factors

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e670-e671

2022

Link zum Volltext

Verfügbarkeit prüfen

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis

Alimentary pharmacology & therapeutics, 2022-02, Vol.55 (3), p.302-310

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis

Digestive diseases and sciences, 2023-06, Vol.68 (6), p.2624-2634

2023

Link zum Volltext

Verfügbarkeit prüfen

Tu1480: EFFICACY AND SAFETY OF TOFACITINIB IN ULCERATIVE COLITIS PATIENTS WITH EXTRAINTESTINAL MANIFESTATIONS IN OCTAVE OPEN

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-979

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis

Mesalazine for the treatment of inflammatory bowel disease

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

Is 5-ASA still the treatment of choice for ulcerative colitis?

Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies

Methodology for high-quality studies on course and prognosis of inflammatory bowel disease

Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis

Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

The Role of Portal Vein Thrombosis in the Clinical Course of Inflammatory Bowel Diseases: Report on Three Cases and Review of the Literature

Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments

Tu1719 ACHIEVEMENT OF STRINGENT HISTOLOGIC AND COMPOSITE ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Tu1735 TREATMENT OUTCOME OF TOFACITINIB DOSE REDUCTION TO 5 MG TWICE DAILY (BID) VS REMAINING ON 10 MG BID IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION ON 10 MG BID: UPDATED 30 MONTH DATA FROM THE DOUBLE-BLIND, RANDOMIZED RIVETING STUDY

Tu1869 TIME TO LOSS OF EFFICACY AMONG PATIENTS IN REMISSION FOLLOWING INDUCTION TREATMENT WITH TOFACITINIB 10 MG BID WHO REDUCED TOFACITINIB DOSE OR DISCONTINUED TOFACITINIB IN OCTAVE SUSTAIN

Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review

130 WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS

S924 Cardiovascular Outcome and Cancer Risk in Adult Patients With Ulcerative Colitis in Routine Clinical Care: The Effect of Cardiovascular Risk-Enrichment Factors

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis

Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis

Tu1480: EFFICACY AND SAFETY OF TOFACITINIB IN ULCERATIVE COLITIS PATIENTS WITH EXTRAINTESTINAL MANIFESTATIONS IN OCTAVE OPEN

Suchergebnisse filtern